Literature DB >> 8172204

Diuretic drugs and the treatment of edema: from clinic to bench and back again.

D H Ellison1.   

Abstract

Despite wide variations in dietary NaCl intake, homeostatic mechanisms ensure that renal NaCl excretion matches intake at steady state. This does not imply, however, that extracellular fluid volume is maintained within narrow limits. In contrast with blood pressure, which appears to be tightly controlled, extracellular fluid volume varies significantly, even in normal individuals, when dietary NaCl intake changes. Cardiac, liver, or renal disease can perturb the relationship between NaCl intake and extracellular fluid volume and lead to symptomatic edema. All major classes of diuretic drugs in use today were developed between 1950 and 1970. These drugs were developed empirically, without knowledge of specific ion transport pathways, but experimental work during the past 15 years has shown that each major class of diuretic inhibits a specific ion transport protein in the kidney. These transport proteins have been characterized physiologically and the mechanisms by which each diuretic drug inhibits ion transport have been defined. Antibodies directed against these transport proteins have localized ion transport pathways to specific cell types along the nephron. Most recently, isoforms of each class of diuretic-sensitive Na transport pathway have been cloned. Ongoing experimental work is aimed at exploring relationships between families of transporters, determining the structural prerequisites for ion transport, and studying molecular mechanisms of transport regulation. Treatment of edema with diuretics is often straightforward, but can lead to adaptive changes in nephron structure and function. These adaptations can limit the effectiveness of diuretic drugs; maneuvers aimed at blocking these processes can be effective approaches to patients who are resistant to diuretic drugs.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8172204     DOI: 10.1016/s0272-6386(12)70272-x

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  11 in total

Review 1.  [Modern differential therapy with diuretics].

Authors:  D Fliser; H Haller
Journal:  Internist (Berl)       Date:  2004-05       Impact factor: 0.743

Review 2.  Diuretic use in renal disease.

Authors:  Domenic A Sica
Journal:  Nat Rev Nephrol       Date:  2011-12-20       Impact factor: 28.314

Review 3.  Resistance of diuretics.

Authors:  B D Rose
Journal:  Clin Investig       Date:  1994-09

4.  Cirrhotic ascites review: Pathophysiology, diagnosis and management.

Authors:  Christopher M Moore; David H Van Thiel
Journal:  World J Hepatol       Date:  2013-05-27

5.  Determinants of Diuretic Responsiveness and Associated Outcomes During Acute Heart Failure Hospitalization: An Analysis From the NHLBI Heart Failure Network Clinical Trials.

Authors:  Michael S Kiernan; Susanna R Stevens; W H Wilson Tang; Javed Butler; Kevin J Anstrom; Edo Y Birati; Justin L Grodin; Divya Gupta; Kenneth B Margulies; Shane LaRue; Victor G Dávila-Román; Adrian F Hernandez; Lisa de Las Fuentes
Journal:  J Card Fail       Date:  2018-03-01       Impact factor: 5.712

6.  The added-up albumin enhances the diuretic effect of furosemide in patients with hypoalbuminemic chronic kidney disease: a randomized controlled study.

Authors:  Bunyong Phakdeekitcharoen; Kochawan Boonyawat
Journal:  BMC Nephrol       Date:  2012-08-29       Impact factor: 2.388

7.  The cardiorenal syndrome: a review.

Authors:  B N Shah; K Greaves
Journal:  Int J Nephrol       Date:  2010-12-28

8.  Increased expression of renal TRPM6 compensates for Mg(2+) wasting during furosemide treatment.

Authors:  Annelies A van Angelen; AnneMiete W van der Kemp; Joost G Hoenderop; René J Bindels
Journal:  Clin Kidney J       Date:  2012-11-07

Review 9.  Clinical Use of Diuretics in Heart Failure, Cirrhosis, and Nephrotic Syndrome.

Authors:  Ahmed Hassaan Qavi; Rida Kamal; Robert W Schrier
Journal:  Int J Nephrol       Date:  2015-07-29

10.  Angiotensin-(1-7) inhibits sodium transport via Mas receptor by increasing nitric oxide production in thick ascending limb.

Authors:  Paula Dibo; Rodrigo O Marañón; Kiran Chandrashekar; Fernando Mazzuferi; Guillermo B Silva; Luis A Juncos; Luis I Juncos
Journal:  Physiol Rep       Date:  2019-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.